Skip to main content

Table 1 Clinical and biochemical parameters during different study periods

From: Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels

   Placebo ARB ARB + HCT
Systolic blood pressure (mmHg) RS 143 (4) 135 (3) 125 (3)†‡
LS 136 (3)* 128 (3)* 121 (2)†‡
Diastolic blood pressure (mmHg) RS 86 (2) 80 (2) 75 (1)†‡
LS 83 (1)* 78 (1) 74 (1)†‡
Plasma potassium concentration (mmol/l) RS 4.3 ± 0.1 4.4 ± 0.1 4.0 ± 0.1†‡
LS 4.3 ± 0.1 4.5 ± 0.1 4.0 ± 0.1†‡
24 h sodium excretion (mmol/day) RS 200 ± 10 197 ± 11 193 ± 11
LS 89 ± 10* 92 ± 8* 93 ± 8*
Creatinine clearance (ml/min) RS 85 (73–98) 90 (77–106) 81 (69–95)
LS 80 (67–94) 79 (67–93)* 72 (61–85)*
Proteinuria (g/day) RS 3.4 (2.6–4.3) 2.3 (1.8–3.0) 1.3 (1.0–1.7)†‡
LS 2.3 (1.7–3.1)* 1.3 (0.9–1.7)* 0.9 (0.6–1.2)*†‡
Active plasma renin concentration (ng AI/ml x h) RS 15 (12–18) 33 (23–45) 64 (47–87)†‡
LS 19 (15–23) 51 (38–70)* 130 (103–163)*†‡
Plasma aldosterone concentration (ng/l) RS 66 (48–91) 57 (41–79) 96 (74–125)
LS 106 (73–152) 113 (86–149)* 164 (129–207)*†‡
Aldosterone-to-renin ratio (ng/ng AI × h) RS 19 (13–26) 7 (4–11) 6 (4–9)
LS 22 (14–32) 9 (6–13) 5 (4–7)†‡
  1. ARB angiotensin receptor blocker (losartan 100 mg/day), HCT hydrochlorothiazide (25 mg/day), RS regular sodium intake, LS low sodium intake
  2. *P < 0.05 vs regular sodium on same treatment (effect of LS)
  3. P < 0.05 vs placebo on same sodium diet
  4. P < 0.05 vs ARB on same sodium diet (effect of HCT)